Family conferences and shared prioritization to improve patient safety in the frail elderly

Family conferences and shared prioritization to improve patient safety in the frail elderly - COFRAIL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00015055

Enrollment

670

Registered

2019-02-06

Start date

2019-03-31

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R54

Interventions

Group 1: Family conferences with GPs (general practitioners), patients and relatives to enhance shared prioritisation on pharmacotherapy Group 2: care as usual

Eligibility

Sex/Gender

All

Age

70 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Positive screening of frailty in a short screening questionnaire answered by the GP utilising the CSHA Clinical Frailty Scale. Patients at the levels 5-7 are eligible for participating in this trial. 2) Regular intake of five or more different drugs per day (Polypharmacy) 3) Care dependency (Pflegestufe / level if care 1 or higher) or comparable status 4) Either nursing care at home by informal family carers alone or supported by professional carers.

Exclusion criteria

Exclusion criteria: 1) moderate or high dementia 2) not under legal guardianship 3) reduced life expectancy of less than 6 months (palliative care) 4) living in a nursing home 5) no fluent German language skills of patients and family carer OR no availability of a translator

Design outcomes

Primary

Measure	Time frame
Hospitalisation rate reported by patients, collected by study nurses during home visits (from March 1st, 2020 by telephone calls) at baseline (t0), after 6 months (t1) and after 12 months (t2).	—

Secondary

Measure	Time frame
1) Total number of medications (collected by study nurses during home visits) 2) Drug Burden Index (DBI) defined as the number of anticholinergic and sedative medications 3) prevalence of PIM 4) Weakness measured by grip strength using a dynamometer 5) Cognition: Two short cognitive subtests from the CERAD neuropsychological test battery: Episodic memory, Executive function 6) Psychological status measured by the Geriatric Depression Scale (GDS) 7) Mobility measured by the Timed Up & Go - Test (fom March 1st, 2020 no longer be carried out due to conversion to telephone data collection) 8) Health related quality of life (EQ-5D) 9) Activities in daily living (Barthel-Index) 10) Weight (self-reported) 11) Rate of self-reported falls All of these data will be collected at baseline (t0), after 6 months (t1) and after 12 months (t2).	—

Measure

Time frame

1) Total number of medications (collected by study nurses during home visits) 2) Drug Burden Index (DBI) defined as the number of anticholinergic and sedative medications 3) prevalence of PIM 4) Weakness measured by grip strength using a dynamometer 5) Cognition: Two short cognitive subtests from the CERAD neuropsychological test battery: Episodic memory, Executive function 6) Psychological status measured by the Geriatric Depression Scale (GDS) 7) Mobility measured by the Timed Up & Go - Test (fom March 1st, 2020 no longer be carried out due to conversion to telephone data collection) 8) Health related quality of life (EQ-5D) 9) Activities in daily living (Barthel-Index) 10) Weight (self-reported) 11) Rate of self-reported falls All of these data will be collected at baseline (t0), after 6 months (t1) and after 12 months (t2).

—

Countries

Germany

Contacts

Public ContactAchim Mortsiefer

Heinrich-Heine-Universität Düsseldorf, Medizinische Fakultät, Institut für Allgemeinmedizin

achim.mortsiefer@uni-wh.de+492118117771

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 28, 2026